GSK Adds 650,000 Shares to Treasury in Ongoing Buyback Programme

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK plc has repurchased 650,000 ordinary shares on 5 March 2026 under its ongoing share buyback programme, at prices between 2,072p and 2,135p and a volume-weighted average price of 2,102.05p. The shares will be held in treasury, taking total buybacks since 17 February 2026 to 6,466,000 shares and leaving 4,069,805,394 shares in issue and 6.05% of voting rights now represented by treasury stock, information shareholders can use for regulatory disclosure calculations.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on the research, development and commercialisation of medicines and vaccines. The group targets major therapeutic areas such as infectious diseases, respiratory conditions and oncology, and it is a constituent of the UK large-cap equity market with a broad international shareholder base.

Average Trading Volume: 8,996,167

Technical Sentiment Signal: Buy

Current Market Cap: £84.77B

See more data about GSK stock on TipRanks’ Stock Analysis page.